-
公开(公告)号：US20200297741A1
公开(公告)日：2020-09-24
申请号：US16604599
申请日：2018-04-11
发明人： SÉBASTIEN APCHER , ALISON PIERSON , MATHILDE BOULPICANTE , RENKO ZAFIARISOA DOLOR , MOUAD ALAMI , ROMAIN DARRIGRAND
IPC分类号： A61K31/665 , A61K45/06 , A61P35/00 , A61K31/352
摘要： The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
-
公开(公告)号：US10765710B2
公开(公告)日：2020-09-08
申请号：US15325576
申请日：2015-07-16
IPC分类号： A61K35/768 , A61K35/28 , C07K16/20 , C07K16/30 , C12N5/00 , A61K9/00 , A61K38/19 , A61K39/395 , C07K16/28 , C12N7/00 , A61K39/00
摘要： The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising an oncolytic virus and one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of an oncolytic virus and one or more immune checkpoint modulator(s).
-
63.发明申请公开(公告)号：US20200253996A1
公开(公告)日：2020-08-13
申请号：US16651719
申请日：2018-10-01
申请人： UNIVERSITE PARIS-SUD , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT GUSTAVE-ROUSSY
发明人： Samir MESSAOUDI , Mouad ALAMI , Jean-Daniel BRION , Amélie CHABRIER , Adam TELERMAN , Robert AMSON
IPC分类号： A61K31/706 , A61K31/7068 , A61P35/00 , A61K31/015 , A61K31/085 , A61K31/03 , A61K31/09 , A61K31/235 , A61K31/11 , A61K31/165 , A61K31/352 , A61K31/404 , A61K31/472 , A61K31/382 , A61K31/704 , A61K31/197 , A61K31/24 , A61K31/135
摘要： The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.
-
64.发明申请公开(公告)号：US20200071766A1
公开(公告)日：2020-03-05
申请号：US16313659
申请日：2017-07-03
发明人： Michiels STEFAN , Mohamed Amine BAYAR , Fabrice ANDRE , Carmen CRISCITIELLO , Giuseppe CURIGLIANO
IPC分类号： C12Q1/6886
摘要： The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).
-
公开(公告)号：US20190201480A1
公开(公告)日：2019-07-04
申请号：US16243654
申请日：2019-01-09
申请人： INSTITUT CURIE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT GUSTAVE ROUSSY , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM) , UNIVERSITE RENE DESCARTES - PARIS V
发明人： Eric DEUTSCH , Johannes LUDGER , Michele MONDINI , Mevyn NIZARD , Jean-Luc PERFETTINI , Eric TARTOUR , Thi TRAN
CPC分类号： A61K38/164 , A61K41/0038 , A61K47/6415 , A61K47/646 , A61N5/10 , A61N2005/1098
摘要： Disclosed is a composition for use in the prevention or treatment of a subject suffering from a cancer in combination with radiotherapy, wherein the composition includes a conjugate, eventually associated with pharmaceutically acceptable carrier, the conjugate including i) the Shiga Toxin B subunit (STxB), a fragment or a derivative thereof; and ii) at least one epitope associated with the cancer.
-
公开(公告)号：US20180364241A1
公开(公告)日：2018-12-20
申请号：US16061667
申请日：2016-12-16
IPC分类号： G01N33/574
摘要： The present invention relates to a method for assessing the response of a patient to a treatment with anti-PD-1/PDL-1 drugs based on the status of the VHL gene (von Hippel-Lindau).
-
67.发明申请公开(公告)号：US20180105574A1
公开(公告)日：2018-04-19
申请号：US15559984
申请日：2016-03-21
申请人： Universite Paris Descartes , Assistance Publique - Hopitaux de Paris , Universite Paris - SUD , Unviversite Pierre et Marie Curie (Paris 6) , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Institut Gustave-Roussy
发明人： Nicolas Dupin , Philippe Grange , Vincent Calvez , Joël Raingeaud
CPC分类号： C07K14/75 , A61K9/0014 , A61K9/0019 , A61K38/00 , A61P17/06 , A61P17/10 , A61P29/00 , C07K2319/00 , C12N7/00
摘要： A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.
-
68.发明授权公开(公告)号：US09938528B2
公开(公告)日：2018-04-10
申请号：US15534321
申请日：2015-12-10
申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paris-Sud , Institut Gustave Roussy , Universite Paris Descartes , Universite Pierre et Marie Curie (Paris 6) , Institut Pasteur , Istituto Nazionale per Le Malattie Infettive IRCCS Lazzaro Spallanzani , Assistance Publique-Hopitaux de Paris (APHP)
IPC分类号： C12N15/11 , C12N15/113 , A61K45/06 , A61K31/683 , A61K31/5517 , A61K31/165 , A61K31/395 , A61K31/17 , A61K31/713 , C12Q1/18
CPC分类号： C12N15/113 , A61K31/165 , A61K31/17 , A61K31/395 , A61K31/5517 , A61K31/683 , A61K31/7088 , A61K31/713 , A61K45/06 , C12N15/1132 , C12N2310/14 , C12N2320/31 , C12Q1/18 , A61K2300/00
摘要： The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.
-
69.发明申请公开(公告)号：US20170342411A1
公开(公告)日：2017-11-30
申请号：US15534321
申请日：2015-12-10
申请人： NSERM (Institut National de la Sante et la Recherc Medicale) , Universite Paris-Sud , Institut Gustave Roussy , Universite Paris Descartes , Universite Pierre et Marie Curie (Paris 6) , Institut Pasteur , Istituto Nazionale per Le Malattie Infettive IRCCS Lazzaro Spallanzani , Assistance Publique-Hopitaux de Paris (APHP)
IPC分类号： C12N15/113 , A61K31/713 , A61K31/17 , A61K31/395 , A61K31/165 , A61K31/683 , A61K31/5517 , C12Q1/18 , A61K45/06
CPC分类号： C12N15/113 , A61K31/165 , A61K31/17 , A61K31/395 , A61K31/5517 , A61K31/683 , A61K31/7088 , A61K31/713 , A61K45/06 , C12N15/1132 , C12N2310/14 , C12N2320/31 , C12Q1/18 , A61K2300/00
摘要： The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.
-
70.发明申请公开(公告)号：US20170283499A1
公开(公告)日：2017-10-05
申请号：US15316074
申请日：2015-06-05
申请人： UNIVERSITE SCIENCES TECHNOLOGIES LILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSTITUT GUSTAVE ROUSSY , CELLVAX , UNIVERSITE DU DROIT ET DE LA SANTE LILLE 2 , UNIVERSITE PARIS-SUD
发明人： Nadira Delhem , Pierre Busson , Olivier Morales , Clement Barjon , Dhafer Mrizak , Claire Lhuillier , Rami Mustapha
IPC分类号： C07K16/28 , A61K39/395 , C07K16/30 , A61K45/06
CPC分类号： C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/30 , C07K16/3092 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
138 条记录 (耗时 0.032 秒)
